Adri Chakraborty

Mapping case manager care-coordination workflows across inpatient, emergency, and discharge transitions at a 1,950-bed acute psychiatric hospital. Quantifying the operational value of case management and building an interactive dashboard for non-clinical audiences.

Delivered 3 independent client engagements end to end, advising biotech and CRO leadership on AI and digital methods in bioanalytical and clinical development workflows. Helped clients avoid ~$500K in low-value spend through go/no-go recommendations on 10+ GenAI programs.

Owned 4 client bioanalytical discovery portfolios end to end, including PK and ADA, leading a team of 4 scientists. Drove PK, ADA, and clinical biomarker decisions by designing fit-for-purpose ligand-binding assays and flow cytometry methods.

Shortened leadership decision time ~30% by synthesizing complex scientific and clinical evidence into a patient-stratification strategy for a hematologic oncology program. Built a regulatory-ready validation package ahead of plan by expanding to a 3-site clinical network.

Kept a $10M+ ARPA-H-funded program on budget and aligned to milestones by advising on scope, KPIs, and budget framework. Guided portfolio entry into 3 priority indications through market assessments and competitive landscape analysis.

Led functional characterization of antibody-drug conjugate candidates for glioblastoma through lead selection, including cytotoxicity and potency assays. Managed a $600K annual budget and vendor relationships.

Identified and validated novel neuro-inflammatory and vascular/lymphatic biomarker panels from human adipose punch biopsies. Ran clinical operations for the 2019 FDRS Phase-I Lipedema trial, designing clinical protocols, SOPs, and eCRFs.

Pursuing a Health Sector MBA with an expected graduation in May 2029.

Earned a PhD in Cell and Molecular Biology in December 2017.

Completed a Master of Science in Regenerative Medicine in July 2009.

Earned a Bachelor of Science in Biotechnology in July 2007.